title: Contingency management for the treatment of antipsychotic-induced weight gain: a randomized controlled pilot study.
abstract: OBJECTIVE
  Weight gain is common for individuals with serious mental illness (SMI) receiving antipsychotic drug therapy. Contingency management (CM) is a behavioral intervention that rewards positive performance and has demonstrated effectiveness in reducing drug use in SMI populations. This study evaluated the feasibility of using CM to promote weight loss in individuals with SMI over 8 weeks.
  
  
  METHODS
  30 individuals (BMI ≥ 28 kg/m(2)) were randomized to one of three conditions: i) The combination of a standardized lifestyle modification (LM) program for individuals with SMI and payment for group attendance (CM(attendance)), ii) The combination of LM and payment for weight loss (CM(weight)), and iii) waitlist control (CON). After the waitlist period, those participants joined a LM group and received payment for behavioral change (CM(behavior)).
  
  
  RESULTS
  Subjects in the CM(attendance) and in the CM(weight) group lost a mean of 1.16 kg and 1.23 kg, respectively, while subjects in the CON gained a mean of 0.68 kg. Subjects receiving CM(behavior), lost a mean of 2.54 kg, which was a significant weight loss compared to the control period.
  
  
  CONCLUSIONS
  LM supplemented with CM may facilitate weight loss in patients taking antipsychotic medications; financial reimbursement for behavioral change may be particularly effective in this population.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA. Jose516@hotmail.com
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Ratliff
authors.forename: Laura B
authors.initials: LB
authors.lastname: Palmese
authors.forename: K Melek
authors.initials: KM
authors.lastname: Tonizzo
authors.forename: Lydia
authors.initials: L
authors.lastname: Chwastiak
authors.forename: Cenk
authors.initials: C
authors.lastname: Tek
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001521:Behavior Therapy / Q000379:methods*; D015992:Body Mass Index; D005260:Female; D015438:Health Behavior; D006801:Humans; D008019:Life Style; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced / Q000523:psychology / Q000628:therapy*; D010349:Patient Compliance; D010865:Pilot Projects; D012201:Reward; D014850:Waiting Lists; D015430:Weight Gain; D015431:Weight Loss; D061217:Weight Reduction Programs
chemical_list: D014150:Antipsychotic Agents